Skip to content

The development of mmAbs dates from 40 years ago when the introduction of the hybridoma technique by Köhler and Milstein in 1975 made it possible to obtain pure mAbs in large quantities. Eleven years later, the Food and Drug Administration (FDA) approved the use of monoclonal antibodies as treatment.

Since then, investment and research in this treatment modality have grown exponentially. In 2019, seven of the ten most used medicines on the planet used mAbs.

The increase in the incidence of cancer and the persistence of infectious diseases pandemics, including dengue and zika, increased the demand for antibodies. These mAbs will likely replace, in the near future, antiviral drugs in the prevention and treatment of infectious diseases.

In 2017, the potential of a new solution for the prevention and treatment of infectious diseases caught the attention of Dr. David Watkins, Dr. Esper Kallas and Dr. Dennis Burton, all three who were previously dedicated to HIV research.

From 2000 to 2020, they published more than 900 scientific articles in specialized journals about the numerous possibilities for treatment for infectious diseases, each with a different expertise. While Dr. Burton specializes in the discovery of mAbs, Dr. Watkins has experience in pre-clinical testing of prevention and treatment modalities in relevant animal models, and Dr. Kallás has extensive experience in human clinical trials.

With the complementary scientific talents of Drs., Burton, Watkins and Kallas, along with the many years of business experience of Michael Wyand, MABLOC was born. A dedicated initiative was born to bring a range of mAbs against various infectious diseases and to contribute to the development of effective solutions to current and future pandemics.